How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Lumpy Skin Disease Vaccines Market
- By Vaccine Type: Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, Subunit Vaccine
- By Animal Type: Cattle, Buffalo, Other Bovines
- By Application: Preventive Vaccination, Therapeutic Vaccination
- By End User: Veterinary Hospitals, Animal Farms, Government Veterinary Services, Research Institutes
- By Distribution Channel: Direct Sales, Veterinary Pharmacies, Online Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Live Attenuated Vaccine leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Lumpy Skin Disease Vaccines Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boehringer Ingelheim
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Zoetis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →MSD Animal Health (Merck)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Indian Immunologicals Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Vetoquinol
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Biovet
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →HIPRA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Janssen Animal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ceva Santé Animale
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Virbac
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Elanco Animal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Kemin Industries
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Phibro Animal Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Live Attenuated Vaccine38.5
- Inactivated Vaccine24.8
- Recombinant Vaccine17.5
- Subunit Vaccine19.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boehringer Ingelheim11.2
- Zoetis28.9
- MSD Animal Health (Merck)13.7
- Bharat Biotech4.5
- Indian Immunologicals Limited9.2
- Vetoquinol4.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe21.8
- Asia Pacific22.2
- Latin America13.4
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | 91 | 90 | 88 | 97 | 83 | 80 | 88 |
| Zoetis | 90 | 89 | 90 | 85 | 92 | 90 | 89 |
| MSD Animal Health (Merck) | 84 | 82 | 81 | 76 | 86 | 76 | 81 |
| Bharat Biotech | 60 | 57 | 66 | 61 | 58 | 68 | 62 |
| Indian Immunologicals Limited | 54 | 51 | 77 | 70 | 69 | 52 | 62 |
| Vetoquinol | 47 | 47 | 58 | 47 | 46 | 71 | 53 |
| Biovet | 66 | 65 | 53 | 59 | 59 | 47 | 58 |
| HIPRA | 42 | 43 | 35 | 51 | 60 | 59 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boehringer Ingelheim
- Zoetis
- MSD Animal Health (Merck)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Zoetis | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| MSD Animal Health (Merck) | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Bharat Biotech | − | − | − | − | ◐ | ◐ |
| Indian Immunologicals Limited | − | − | ◐ | ✓ | ◐ | ◐ |
| Vetoquinol | − | − | ◐ | ◐ | − | ✓ |
| Biovet | ◐ | ✓ | − | ◐ | − | − |
| HIPRA | − | − | − | − | ✓ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Contender3
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Vaccine Type in North America, then scale across Lumpy Skin Disease Vaccines Market — a $92M beachhead inside a $1.36B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Live Attenuated Vaccine
Best fit — highest urgency & budget in Vaccine Type.
Inactivated Vaccine
Strong fit — clear ROI and a fast path to value.
Recombinant Vaccine
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Animal Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lumpy Skin Disease Vaccines Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Lumpy Skin Disease Vaccines Market is a resilient opportunity — $2.54B by 2033, compounding at 3.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.4% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Animal Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Lumpy Skin Disease Vaccines Market — a $5.83B market by 2033. Plan: grow share from 7.1% to 13.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 13.1% | At risk |
| Revenue | $435M | $764M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.0% | 38.7% | Behind |
| Customer retention | 86.9% | 94.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Animal Type capability
A defensible second engine — invest in Animal Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Animal Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $112M capacity & capability investment
- Greenlight bolt-on M&A in Animal Type
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Sales deck · value proposition
Win the Lumpy Skin Disease Vaccines Market conversation — a $4.95B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lumpy Skin Disease Vaccines Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Lumpy Skin Disease Vaccines Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Lun Cotton Flax Yarn Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportLunch Container Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportLung Adenocarcinoma Drug Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportLung Cancer Drugs Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportLung Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$901M market · 2025 base year
View reportLung Management Products Market
Market size, share, segmentation and regional forecast.
$644M market · 2025 base year
View reportLung Net (L Net) Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportLung Stent Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportLung Stents Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportLuo Wenbu Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportLuohanfruit Tincture Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportLupinus Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy